Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

| Create an account https://orcid.org

Search life-sciences literature (45,104,206 articles, preprints and more)

Search results

1-25 of 102 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

The Association Between Baseline Hepatic or Renal Function and Clinical Outcomes for Patients With Non-Small Cell Lung Cancer Treated With a PD-1/PD-L1 Blocking Antibody Using Real-World and Trial Data.
Liu Q, Mathur R, Xu Y, Torres AZ, Miksad RA, Liu C, Smithson H, Wang Y, Zhu H, Booth B, Huang SM, Zhi J, Sridhara R, Blumenthal GM, Larkins E, Mishra-Kalyani PS, Rivera DR, Kluetz PG, Sharon E
Clin Pharmacol Ther, 113(5):1139-1149, 13 Mar 2023
Cited by: 3 articles | PMID: 36790088
Add to export list
Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses.
Norsworthy KJ, Gao X, Ko CW, Pulte ED, Zhou J, Gong Y, Shen YL, Vallejo J, Gwise TE, Sridhara R, Deisseroth AB, Farrell AT, de Claro RA, Blumenthal GM, Pazdur R
J Clin Oncol, 40(8):847-854, 10 Dec 2021
Cited by: 8 articles | PMID: 34890212 | PMCID: PMC8906455
Add to export list Free full text in Europe PMC
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
Chang E, Pelosof L, Lemery S, Gong Y, Goldberg KB, Farrell AT, Keegan P, Veeraraghavan J, Wei G, Blumenthal GM, Amiri-Kordestani L, Singh H, Fashoyin-Aje L, Gormley N, Kluetz PG, Pazdur R, Beaver JA, Theoret MR
Oncologist, 26(10):e1786-e1799, 27 Jul 2021
Cited by: 43 articles | PMID: 34196068 | PMCID: PMC8488782
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.
Mason J, Gong Y, Amiri-Kordestani L, Wedam S, Gao JJ, Prowell TM, Singh H, Amatya A, Tang S, Pazdur R, Kuhn P, Blumenthal GM, Beaver JA
JCO Clin Cancer Inform, 5:758-767, 01 Jun 2021
Cited by: 2 articles | PMID: 34297598 | PMCID: PMC8807021
Add to export list Free full text in Europe PMC
Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer.
Bonomi P, Stuccio N, Delgra CJ, Chuk MK, Spira A, Deitz AC, Blumenthal GM, Ferris A, Gong Y, He J, Basu Roy U, Selig W
Ther Innov Regul Sci, 54(5):1208-1214, 26 Mar 2020
Cited by: 3 articles | PMID: 32865803
Add to export list
Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases.
Febbo PG, Martin AM, Scher HI, Barrett JC, Beaver JA, Beresford PJ, Blumenthal GM, Bramlett K, Compton C, Dittamore R, Eberhard DA, Edelstein D, Godsey J, Gruen A, Hanlon SE, Hicks J, Hovelson D, Hullings M, Johann D, [...] Leiman LC
Clin Pharmacol Ther, 107(4):730-734, 04 Feb 2020
Cited by: 10 articles | PMID: 32017048 | PMCID: PMC7158216
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Development, Validation, and Regulatory Considerations for a Liquid Biopsy Test.
Tsui DWY, Blumenthal GM, Philip R, Barrett JC, Montagut C, Bramlett K, Ladanyi M, Ghosh S
Clin Chem, 66(3):408-414, 01 Mar 2020
Cited by: 5 articles | PMID: 32091082
Add to export list
Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group.
Forde PM, Bonomi P, Shaw A, Blumenthal GM, Ferris A, Patel C, Melemed A, Basu Roy U, Ramamoorthy A, Liu Q, Burns T, Gainor JF, Lovly C, Piotrowska Z, Lehman J, Selig W
Clin Lung Cancer, 21(4):295-307, 26 Feb 2020
Cited by: 6 articles | PMID: 32201247
Add to export list
Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer.
Agrawal S, Haas NB, Bagheri M, Lane BR, Coleman J, Hammers H, Bratslavsky G, Chauhan C, Kim L, Krishnasamy VP, Marko J, Maher VE, Ibrahim A, Cross F, Liu K, Beaver JA, Pazdur R, Blumenthal GM, Singh H, [...] Apolo AB
JAMA Oncol, 6(1):133-141, 01 Jan 2020
Cited by: 8 articles | PMID: 31750870 | PMCID: PMC8127869
Add to export list Free full text in Europe PMC
Application of the Lung Immune Prognostic Index From Research to Clinical Practice-Reply.
Kazandjian D, Gong Y, Blumenthal GM
JAMA Oncol, 6(2):300-301, 01 Feb 2020
Cited by: 2 articles | PMID: 31774473
Add to export list
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1.
Narayan P, Wahby S, Gao JJ, Amiri-Kordestani L, Ibrahim A, Bloomquist E, Tang S, Xu Y, Liu J, Fu W, Song P, King-Kallimanis BL, Hou S, Gong Y, Kalavar S, Ghosh S, Philip R, Goldberg KB, Theoret MR, [...] Beaver JA
Clin Cancer Res, 26(10):2284-2289, 30 Jan 2020
Cited by: 75 articles | PMID: 32001481
Add to export list
Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer.
Apolo AB, Milowsky MI, Kim L, Inman BA, Kamat AM, Steinberg G, Bagheri M, Krishnasamy VP, Marko J, Dinney CP, Bangs R, Sweis RF, Maher VE, Ibrahim A, Liu K, Werntz R, Cross F, Beaver JA, Singh H, [...] Agrawal S
JAMA Oncol, 5(12):1790-1798, 01 Dec 2019
Cited by: 5 articles | PMID: 31670753 | PMCID: PMC8211913
Add to export list Free full text in Europe PMC
FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults.
Li RJ, Jin R, Liu C, Cao X, Manning ML, Di XM, Przepiorka D, Namuswe F, Deisseroth A, Goldberg KB, Blumenthal GM, Pazdur R
Clin Cancer Res, 26(2):328-331, 23 Aug 2019
Cited by: 12 articles | PMID: 31444252
Add to export list
An Analysis of Recent FDA Oncology Scientific Publications.
Schneider JA, Miklos AC, Onken J, Gong Y, Calcagno AM, Blumenthal GM, Aragon R, Pazdur R
Oncologist, 25(3):266-270, 26 Nov 2019
Cited by: 3 articles | PMID: 32162806 | PMCID: PMC7066718
Add to export list Free full text in Europe PMC
Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
Kim J, Nair A, Keegan P, Beaver JA, Kluetz PG, Pazdur R, Chuk M, Blumenthal GM
Oncologist, 25(4):348-354, 17 Dec 2019
Cited by: 3 articles | PMID: 32297444 | PMCID: PMC7160417
Add to export list Free full text in Europe PMC
Global Variation in Opioid Use in Prostate Cancer Trials.
Roydhouse JK, Suzman DL, Menapace LA, Mishra-Kalyani PS, Sridhara R, Blumenthal GM, Beaver JA, Pazdur R, Kluetz PG
JAMA Oncol, 5(11):e192971, 14 Nov 2019
Cited by: 2 articles | PMID: 31513232 | PMCID: PMC6743059
Add to export list Free full text in Europe PMC
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ, Cheng J, Bloomquist E, Sanchez J, Wedam SB, Singh H, Amiri-Kordestani L, Ibrahim A, Sridhara R, Goldberg KB, Theoret MR, Kluetz PG, Blumenthal GM, Pazdur R, Beaver JA, Prowell TM
Lancet Oncol, 21(2):250-260, 16 Dec 2019
Cited by: 136 articles | PMID: 31859246
Add to export list
FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
Przepiorka D, Luo L, Subramaniam S, Qiu J, Gudi R, Cunningham LC, Nie L, Leong R, Ma L, Sheth C, Deisseroth A, Goldberg KB, Blumenthal GM, Pazdur R
Oncologist, 25(2):e328-e334, 22 Oct 2019
Cited by: 65 articles | PMID: 32043777 | PMCID: PMC7011641
Add to export list Free full text in Europe PMC
Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer.
Kazandjian D, Gong Y, Keegan P, Pazdur R, Blumenthal GM
JAMA Oncol, 5(10):1481-1485, 01 Oct 2019
Cited by: 120 articles | PMID: 31343662 | PMCID: PMC6659150
Add to export list Free full text in Europe PMC
FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jen EY, Gao X, Li L, Zhuang L, Simpson NE, Aryal B, Wang R, Przepiorka D, Shen YL, Leong R, Liu C, Sheth CM, Bowen S, Goldberg KB, Farrell AT, Blumenthal GM, Pazdur R
Clin Cancer Res, 26(3):532-536, 23 Sep 2019
Cited by: 33 articles | PMID: 31548341
Add to export list
A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer.
Komiya T, Memmott RM, Blumenthal GM, Bernstein W, Ballas MS, De Chowdhury R, Chun G, Peer CJ, Figg WD, Liewehr DJ, Steinberg SM, Giaccone G, Szabo E, Kawabata S, Tsurutani J, Rajan A, Dennis PA
Transl Lung Cancer Res, 8(3):247-257, 01 Jun 2019
Cited by: 11 articles | PMID: 31367538 | PMCID: PMC6626857
Add to export list Free full text in Europe PMC
FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome.
Kasamon YL, Chen H, de Claro RA, Nie L, Ye J, Blumenthal GM, Farrell AT, Pazdur R
Clin Cancer Res, 25(24):7275-7280, 31 Jul 2019
Cited by: 31 articles | PMID: 31366601
Add to export list
A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN.
Komiya T, Blumenthal GM, DeChowdhury R, Fioravanti S, Ballas MS, Morris J, Hornyak TJ, Wank S, Hewitt SM, Morrow B, Memmott RM, Rajan A, Dennis PA
Oncologist, 24(12):1510-e1265, 26 Jul 2019
Cited by: 20 articles | PMID: 31350329 | PMCID: PMC6975943
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Model-Informed Drug Development Approach to Expedite Approval: Case of Alectinib in First-Line Anaplastic Lymphoma Kinase + Non-Small Cell Lung Cancer.
Morcos PN, Liu J, Blumenthal GM, Zhao H
Clin Pharmacol Ther, 105(4):826-828, 05 Feb 2019
Cited by: 2 articles | PMID: 30723888
Add to export list
Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer.
Blumenthal GM, Gong Y, Kehl K, Mishra-Kalyani P, Goldberg KB, Khozin S, Kluetz PG, Oxnard GR, Pazdur R
Ann Oncol, 30(5):830-838, 01 May 2019
Cited by: 70 articles | PMID: 30796424
Add to export list

1-25 of 102 results

1 2 3 Next ...

Search life-sciences literature (45,104,206 articles, preprints and more)

Search results

The Association Between Baseline Hepatic or Renal Function and Clinical Outcomes for Patients With Non-Small Cell Lung Cancer Treated With a PD-1/PD-L1 Blocking Antibody Using Real-World and Trial Data.

Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses.

Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.

Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.

Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer.

Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases.

Development, Validation, and Regulatory Considerations for a Liquid Biopsy Test.

Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group.

Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer.

Application of the Lung Immune Prognostic Index From Research to Clinical Practice-Reply.

FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1.

Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer.

FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults.

An Analysis of Recent FDA Oncology Scientific Publications.

Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.

Global Variation in Opioid Use in Prostate Cancer Trials.

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.

FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer.

FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.

A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer.

FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome.

A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN.

Model-Informed Drug Development Approach to Expedite Approval: Case of Alectinib in First-Line Anaplastic Lymphoma Kinase + Non-Small Cell Lung Cancer.

Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer.

Partnerships & funding